GlassScriptPhysician profile
Marquetta Adams
NPI 1942778162
$2,233.29
in general payments reported to CMS, 2019-2025
16 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2024: $388 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $306.74 | 2024-2025 | Flumist Quadrivalent, Airsupra |
| Averitas Pharma INC. | $299.96 | 2025 | Qutenza |
| Inspire Medical Systems, INC. | $142.97 | 2025 | Inspire |
| Abiomed | $137.48 | 2025 | |
| Amgen INC. | $131.64 | 2025 | Repatha |
| Genzyme Corporation | $124.99 | 2025 | |
| Shionogi INC | $124.22 | 2025 | |
| Boston Scientific Corporation | $124.18 | 2025 | Watchman Flx |
| Viiv Healthcare Company | $115.44 | 2025 | Apretude |
| Sandoz INC. | $112.43 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $106.51 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $105.33 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $103.11 | 2025 | Voquezna |
| Corcept Therapeutics | $102.30 | 2024 | Korlym |
| Genentech USA, INC. | $101.07 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $94.92 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marquetta Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.